Action from FDA results in some hospice drug shortages

August 2009
Hospice Management Advisor;Aug2009, Vol. 14 Issue 8, p85
The article focuses on the issues concerning the restrictions made by the U.S. Food and Drug Administration (FDA) over the manufacturing of opioid medications. Due to the restrictions, the hospice industry still are finding shortages of opioid and is scrambling to find alternative pain medication for patients. Moreover, it notes that the biggest concern of the industry was FDA's restrictions on the supply of drugs without talking with health care representative.


Related Articles

  • Announcements.  // Journal of Palliative Medicine;Jul2009, Vol. 12 Issue 7, p663 

    The article offers news briefs related to palliative care in the U.S. The self-assessment examinations (SAEs) from the Logic Extension Resources LXR Store can be an effective learning tools for nurses. The Food and Drug Administration (FDA) is planning to implement restrictions on prescriptions...

  • FDA reverses decision on liquid morphine.  // Hospice Management Advisor;May2009, Vol. 14 Issue 5, p60 

    The article reports on the amendment made by the U.S. Food and Drug Administration (FDA) on a March 30, 2009 decision over the production and manufacturing of unapproved prescription opioids, including liquid morphine, following concerns raised by hospice and palliative care organizations. It...

  • New rules for opioid prescribing.  // Critical Care Alert;Apr2009 Pharmacology, p2 

    The article reports on the restrictions imposed by the Food & Drug Administration (FDA) on the use of opioid drugs in the U.S.

  • Regulation and Compliance Q&A.  // Pharmaceutical Technology;Jul2012, Vol. 36 Issue 7, p20 

    The article provides an answer to a question on how pharmaceutical plants could prepare for the U.S. Food and Drug Administration (FDA) inspections.

  • New FDA Office Monitors Drug Quality.  // Chain Drug Review;3/17/2014, Vol. 36 Issue 5, p94 

    The article offers information on the necessity of creation of a quality testing unit to check drug quality after U.S. Food & Drug Administration (FDA) banned sales of generic medicines in the U.S. manufactured from several Indian manufacturing plants.

  • REMS: red tape, or a remedy for opioid abuse? PORADA, STEPHEN // Journal of Family Practice;Sep2011 Supplement 2, Vol. 60, pS55 

    The author discusses the Risk Evaluation and Mitigation Strategies (REMS), which is an imposed program from the U.S. Food and Drug Administration (FDA). He is critical on the reasons provided by the FDA regarding the program such as to assure that the benefits of opioid analgesics prescription...

  • FDA looking to add REMS for certain opioids.  // Pharmacy Today;Mar2009, Vol. 15 Issue 3, p1 

    The article reports on the move of the Food and Drug Administration (FDA) to require drug manufacturers a Risk Evaluation and Management Strategy (REMS) for opioid drug products in the U.S. The program is to reduce the frequency of drug misuse, abuse and accidental overdose through the...

  • FDA panel rejects REMS proposal for long-acting opioids. Edlin, Mari // Drug Topics;Sep2010, Vol. 154 Issue 9, p39 

    The article reports on the decision of the Food and Drug Administration (FDA) panel to reject FDA's risk evaluation and mitigation strategy (REMS) proposal for long-acting opioids during a meeting held in Adelphi, Maryland. It notes that the proposal would require physicians to receive training...

  • Action About Unapproved Opioids Amended.  // Critical Care Nurse;Aug2009, Vol. 29 Issue 4, p6 

    The article reports on changes which the U.S. Food and Drug Administration made to recommendations on unapproved prescription opioids that it had made on March 30, 2009. The recommendations had asked drug manufacturers to stop the production and distribution of certain unapproved prescription...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics